期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

药物基因组学与非小细胞肺癌个性化治疗的研究 被引量：1

下载PDF
导出
摘要 目的:本文对非小细胞肺癌(NSCLC)化疗药物的基因组学研究现状进行综述,旨在为临床制定化疗方案提供参考。方法:综述在过去的几年里发表的有关顺铂、吉西他宾、紫杉醇、吉非替尼以及培美曲塞等NSCLC化疗药物基因组学研究文章。结果:近年研究发现,除了环境等因素外,不同个体的基因组差异也是造成药物效应差异的主要因素,NSCLC治疗方法的发展在很大程度上取决于药物基因组学的研究与应用。结论:药物基因组学为从NSCLC的综合治疗由标准化过渡到个体化指明了方向。
作者 孙伟
机构地区 天津市胸科医院
出处 《医学理论与实践》 2011年第16期1914-1917,共4页 The Journal of Medical Theory and Practice
关键词 非小细胞肺癌 化学药物治疗 药物基因组学
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献17

  • 1James CM Ho.The State-of-the-Art treatment of non-small cell lung cancer[J].The Hongkong Medical Daily,2008,13(12):13-15.
  • 2Perez-Soler R.Individualized therapy in non-small-cell lung cancer:future versus current clinical practice[J].Oncogene,2009,28(1):38-45.
  • 3Wang L,Wei J,Qian X,et al.ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel[J].BMC Cancer,2008,8:97.
  • 4Bristow RG,Hill RP.Hypoxia and metabolism:Hypoxia,DNA repair and genetic instability[J].Nat Rev Cancer,2008,8(3):180-192.
  • 5Halazonetis TD,Gorgoulis VG,Bartek J.An oncogene-induced DNA damage model for cancer development[J].Science,2008,319(5868):1352-1355.
  • 6Rosell R,Perez-Rocal L,et al.Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression[J].PLoS One,2009,4(5):5133.
  • 7Weberpals J,Garbuio K,O'Brien A,et al.The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer[J].Int J Cancer,2009,124(4):806-815.
  • 8Scagliotti GV,Parikh P,von Pawel J,et al.Phase Ⅲ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in hemotherapy-naive patients with advanced-stage non-small-cell lung cancer[J].J Clin Oncol,2008,26(21):3543-3551.
  • 9Romano D,Giuseppe AL,Elisa G,et al.pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors[J].Pharmacogenomics,2009,10(1):69-80.
  • 10李张云,邓觐云,黄传生,陈悦,周伟华.非小细胞肺癌RRM1蛋白表达与吉西他滨体外药敏相关性的研究[J].江西医药,2009,44(11):1074-1077. 被引量：4

二级参考文献64

  • 1廖日强,林嘉颖,乔贵宾,骆新兰,杨衿记,黄玉娟,吴一龙.非小细胞肺癌组织芯片中RRM1表达和预后因子分析[J].中国肺癌杂志,2006,9(5):423-427. 被引量：20
  • 2Goan YG,Zhou B,Hu E,Mi S,et al. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxy -cytidine in the human KB cancer cell line. Cancer Res, 1999,59, 4204.
  • 3Kurbacher CM ,Cree IA ,Bruckner HW,et al . Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer. Anticancer Drugs ,1998,9(1):51.
  • 4Dumontet C ,Fabianowska-Majewsda K ,Mantincic D ,et al.Common resistance mechanisms to deoxynucleoside analogues in variants of the hum an erythroleukaemic line K562.Br J Haematol,1999, 106(1): 78.
  • 5DavidsonJ D,M aL ,Flagela M ,et al.An increase in the expression of ribonucleotide reductase large subunitl is associated with gemcitabine resistance in non-small cell lung cancer cell lines.Cancer Res ,2004,64(11):3761.
  • 6Ekhart C,Rodenhuis S,Smits P H,et al.An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment[J].Cancer Treat Rev,2009,35(1):18-31.
  • 7Lyseng-Williamson K A,Fenton C.Taxanes for the adjuvant treatment of early breast cancer:systematic review and economic evaluation[J].Health Technol Assess,2007,11(40):1-144.
  • 8Herceq D,Vrbanec D.The role of taxanes in breast cancer chemotherapy:what' s new 15 years after[J].Lijec Vjesn,2009,131(5-6):133-141.
  • 9Nabholtz,Jcan-Marc,Gligorov,et al.The role of taxanes in the treatment of breast[J].Expe Opin Phar,2005,6(7):1073-1094.
  • 10Noguchi S.Predictive factors for response to docetaxel in human breast cancers[J].Cancer Sci,2006,97(9):813-20.

共引文献42

同被引文献17

  • 1吕汪霞,苏丹,马胜林.肺癌耐药机制研究的新进展[J].中国肺癌杂志,2005,8(2):152-155. 被引量：7
  • 2王玲,姚远兵,王卓.多靶点叶酸拮抗剂培美曲塞[J].世界临床药物,2007,28(5):293-298. 被引量：1
  • 3Fry W H,Kotelawala L,Sweeney C,et al. Mechanismsof ErbB receptor negative regulation and relevance incancer[J]. Exp Cell Res,2009, 315(4) :697-706.
  • 4Sharma S V,Bell D W,Settleman J, et al. Epidermalgrowth factor receptor mutations in lung cancer [ J ]. NatRev Cancer, 2007, 7(3) :169-181.
  • 5Giltnane J M, Moeder C B, Camp R L,et al. Quantita-tive multiplexed analysis of ErbB family coexpression forprimary breast cancer prognosis in a large retrospective co-hort[J]. Cancer, 2009, U5( 11) :2400-2409.
  • 6Fujimoto N, Wislez M, Zhang J,et al. High expressionof ErbB family members and their ligands in lung adeno-carcinomas that are sensitive to inhibition of epidermalgrowth factor receptor[ J]. Cancer Res,2005,65 (24):11478-11485.
  • 7Hayashi M, Inokuchi M, Takagi Y, et al. High expres-sion of HER3 is associated with a decreased survival ingastric cancer [ J ]. Clin Cancer Res, 2008,14 ( 23 ):7843-7849.
  • 8Zhang H, Zan J, Yu G, et al. A combination of 3D-QSAR, molecular docking and molecular dynamics simu-lation studies of benzimidazole-quinolinone derivatives asiNOS inhibitors[J]. Int J Mol Sci,2012,13(9) :11210-11227.
  • 9James C M Ho. The State-of-the-Art treatment of non-small cell lung cancer[ J] ? The Hong Kong Medical Dia-ry, 2008, 13(12) : 13-15.
  • 10Paolo C,Marco V,Silvia S,et al. Squamous cell carci-noma of the lung compared with other histotypes showshigher messenger RNA and protein levels for thymidylatesynthase[ J]. Cancer, 2006, 107(7) : 1589-1596.

引证文献1

二级引证文献1

医学理论与实践
2011年 第16期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部